glp-1 agonist therapy information platforms for Weight Loss and Diabetes glp-1_analogs [TUSOM | Pharmwiki]

Characteristics of elderly patients initiating sitagliptin or non-DPP-4-inhibitor oral antihyperglycemic agents: analysis of a cross-sectional US claims database

This once daily 3.0 mg subcutaneous injection demonstrated meaningful weight losses in clinical trials with optimal results occurring when combined with reduced calorie diet and increased physical activity

Thats common, and it doesnt automatically exclude you

This may be related to reduced caloric intake, changes in blood sugar patterns, or direct effects on the central nervous system

Vahle JL, Byrd RA, Blackbourne JL, Martin JA, Sorden SD, Ryan T, Pienkowski T, Rosol TJ, Snyder PW, and Kloppel G